Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk    NOVO B   DK0060534915

NOVO NORDISK

(NOVO B)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
03/18/2019 03/19/2019 03/20/2019 03/21/2019 03/22/2019 Date
338.8(c) 344.5(c) 344.6(c) 344.65(c) 336.35(c) Last
1 614 838 2 790 022 2 135 870 1 833 061 2 172 577 Volume
+1.13% +1.68% +0.03% +0.01% -2.41% Change
More quotes
Financials (DKK)
Sales 2019 118 B
EBIT 2019 51 043 M
Net income 2019 39 369 M
Finance 2019 13 809 M
Yield 2019 2,49%
Sales 2020 126 B
EBIT 2020 54 718 M
Net income 2020 42 943 M
Finance 2020 16 115 M
Yield 2020 2,74%
P/E ratio 2019 20,33
P/E ratio 2020 18,20
EV / Sales2019 5,33x
EV / Sales2020 4,99x
Capitalization 643 B
More Financials
Company
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The... 
Sector
Pharmaceuticals
Calendar
05/03Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK
03/22NOVO NORDISK : Seeks U.S. FDA Approval For Oral Type 2 Diabetes Medication
AQ
03/22NOVO NORDISK : Ex-dividend day for final dividend
FA
03/21NOVO NORDISK : Resolutions from the Annual General Meeting of Novo Nordisk A/S
GL
03/21NOVO NORDISK : files oral semaglutide for US regulatory approval of glycaemic co..
AQ
03/20NOVO NORDISK : Seeks FDA OK for Oral Semaglutide in Adults With Type 2 Diabetes
DJ
03/20NOVO NORDISK : files oral semaglutide for US regulatory approval of glycaemic co..
GL
03/20NOVO NORDISK : settles Victoza patent dispute with Teva in US
AQ
03/18NOVO NORDISK A/S : - Share repurchase programme
AQ
03/18NOVO NORDISK : settles US patent litigation case on Victoza® (liraglutide) with ..
GL
03/15NOVO NORDISK : Team Novo Nordisk Slated to Return to Tour of California
AQ
More news
Analyst Recommendations on NOVO NORDISK
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 2018
Attractive timing with a long term view to go long again
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
08:57aBAYER : CEO says his team retains backing of supervisory board
RE
03/22FDA Rejects Oral Treatment for Type 1 Diabetes - Update
DJ
03/22ALLERGAN : promises independent board chair in next leadership change
RE
03/22FDA Rejects Oral Treatment for Type 1 Diabetes
DJ
03/22UPS to Test In-Home Vaccine Service in U.S. -Reuters
DJ
More sector news : Pharmaceuticals - NEC
Chart NOVO NORDISK
Duration : Period :
Novo Nordisk Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 330  DKK
Spread / Average Target -1,8%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK12.91%97 458
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
PFIZER-4.12%232 343
MERCK AND COMPANY7.70%212 409